tumor lysate particle loaded dendritic cell vaccine (TL-YCWP-DC)

P2, N=187, Completed, Elios Therapeutics, LLC | Phase classification: P2b --> P2

P1/2, N=26, Completed, Elios Therapeutics, LLC | N=45 --> 26

The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial.

The TLPLDC vaccine improved overall survival in patients with DFI >3 months prior to recurrence. These patients have more indolent disease biology and a less immunosuppressive tumor microenvironment, where monotherapy with a cancer vaccine is thought to be more effective. Further study is required to identify patients at initial presentation who are more likely to benefit from the TLPLDC vaccine.